746 related articles for article (PubMed ID: 9499087)
61. Role of the proteasome in membrane extraction of a short-lived ER-transmembrane protein.
Mayer TU; Braun T; Jentsch S
EMBO J; 1998 Jun; 17(12):3251-7. PubMed ID: 9628862
[TBL] [Abstract][Full Text] [Related]
62. Effects of tocotrienol on the intracellular translocation and degradation of apolipoprotein B: possible involvement of a proteasome independent pathway.
Wang Q; Theriault A; Gapor A; Adeli K
Biochem Biophys Res Commun; 1998 May; 246(3):640-3. PubMed ID: 9618265
[TBL] [Abstract][Full Text] [Related]
63. βTrCP is Required for HIV-1 Vpu Modulation of CD4, GaLV Env, and BST-2/Tetherin.
Song YE; Cyburt D; Lucas TM; Gregory DA; Lyddon TD; Johnson MC
Viruses; 2018 Oct; 10(10):. PubMed ID: 30347660
[TBL] [Abstract][Full Text] [Related]
64. Phosphorylation of both phosphoacceptor sites in the HIV-1 Vpu cytoplasmic domain is essential for Vpu-mediated ER degradation of CD4.
Paul M; Jabbar MA
Virology; 1997 May; 232(1):207-16. PubMed ID: 9185604
[TBL] [Abstract][Full Text] [Related]
65. 1,25-Dihydroxyvitamin D3 increases nuclear vitamin D3 receptors by blocking ubiquitin/proteasome-mediated degradation in human skin.
Li XY; Boudjelal M; Xiao JH; Peng ZH; Asuru A; Kang S; Fisher GJ; Voorhees JJ
Mol Endocrinol; 1999 Oct; 13(10):1686-94. PubMed ID: 10517670
[TBL] [Abstract][Full Text] [Related]
66. Mutational analysis of the human immunodeficiency virus type 1 Vpu transmembrane domain that promotes the enhanced release of virus-like particles from the plasma membrane of mammalian cells.
Paul M; Mazumder S; Raja N; Jabbar MA
J Virol; 1998 Feb; 72(2):1270-9. PubMed ID: 9445027
[TBL] [Abstract][Full Text] [Related]
67. Calnexin and other factors that alter translocation affect the rapid binding of ubiquitin to apoB in the Sec61 complex.
Chen Y; Le Cahérec F; Chuck SL
J Biol Chem; 1998 May; 273(19):11887-94. PubMed ID: 9565615
[TBL] [Abstract][Full Text] [Related]
68. 'ER degradation' of a mutant yeast plasma membrane protein by the ubiquitin-proteasome pathway.
Galan JM; Cantegrit B; Garnier C; Namy O; Haguenauer-Tsapis R
FASEB J; 1998 Mar; 12(3):315-23. PubMed ID: 9506475
[TBL] [Abstract][Full Text] [Related]
69. Specific ubiquitin-conjugating enzymes promote degradation of specific nuclear receptor coactivators.
Yan F; Gao X; Lonard DM; Nawaz Z
Mol Endocrinol; 2003 Jul; 17(7):1315-31. PubMed ID: 12663742
[TBL] [Abstract][Full Text] [Related]
70. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes.
Schubert U; Antón LC; Gibbs J; Norbury CC; Yewdell JW; Bennink JR
Nature; 2000 Apr; 404(6779):770-4. PubMed ID: 10783891
[TBL] [Abstract][Full Text] [Related]
71. Proteasome involvement and accumulation of ubiquitinated proteins in cerebellar granule neurons undergoing apoptosis.
Canu N; Barbato C; Ciotti MT; Serafino A; Dus L; Calissano P
J Neurosci; 2000 Jan; 20(2):589-99. PubMed ID: 10632588
[TBL] [Abstract][Full Text] [Related]
72. Ubiquitin-dependent and -independent proteasomal degradation of apoB associated with endoplasmic reticulum and Golgi apparatus, respectively, in HepG2 cells.
Liao W; Chang BH; Mancini M; Chan L
J Cell Biochem; 2003 Aug; 89(5):1019-29. PubMed ID: 12874835
[TBL] [Abstract][Full Text] [Related]
73. Binding of human cytomegalovirus US2 to major histocompatibility complex class I and II proteins is not sufficient for their degradation.
Chevalier MS; Daniels GM; Johnson DC
J Virol; 2002 Aug; 76(16):8265-75. PubMed ID: 12134032
[TBL] [Abstract][Full Text] [Related]
74. The selective proteasome inhibitors lactacystin and epoxomicin can be used to either up- or down-regulate antigen presentation at nontoxic doses.
Schwarz K; de Giuli R; Schmidtke G; Kostka S; van den Broek M; Kim KB; Crews CM; Kraft R; Groettrup M
J Immunol; 2000 Jun; 164(12):6147-57. PubMed ID: 10843664
[TBL] [Abstract][Full Text] [Related]
75. Proteasome-dependent endoplasmic reticulum-associated protein degradation: an unconventional route to a familiar fate.
Werner ED; Brodsky JL; McCracken AA
Proc Natl Acad Sci U S A; 1996 Nov; 93(24):13797-801. PubMed ID: 8943015
[TBL] [Abstract][Full Text] [Related]
76. Multiple proteolytic systems, including the proteasome, contribute to CFTR processing.
Jensen TJ; Loo MA; Pind S; Williams DB; Goldberg AL; Riordan JR
Cell; 1995 Oct; 83(1):129-35. PubMed ID: 7553864
[TBL] [Abstract][Full Text] [Related]
77. Liver alcohol dehydrogenase is degraded by the ubiquitin-proteasome pathway.
Mezey E; Rennie-Tankersley L; Potter JJ
Biochem Biophys Res Commun; 2001 Jul; 285(3):644-8. PubMed ID: 11453641
[TBL] [Abstract][Full Text] [Related]
78. Degradation of trafficking-defective long QT syndrome type II mutant channels by the ubiquitin-proteasome pathway.
Gong Q; Keeney DR; Molinari M; Zhou Z
J Biol Chem; 2005 May; 280(19):19419-25. PubMed ID: 15760896
[TBL] [Abstract][Full Text] [Related]
79. In vivo ubiquitination and proteasome-mediated degradation of p53(1).
Maki CG; Huibregtse JM; Howley PM
Cancer Res; 1996 Jun; 56(11):2649-54. PubMed ID: 8653711
[TBL] [Abstract][Full Text] [Related]
80. Cytosolic components are required for proteasomal degradation of newly synthesized apolipoprotein B in permeabilized HepG2 cells.
Sakata N; Stoops JD; Dixon JL
J Biol Chem; 1999 Jun; 274(24):17068-74. PubMed ID: 10358059
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
